Jasper Therapeutics (JSPR) Non-Current Assets (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Non-Current Assets of $1.1 million for Q4 2025, down 72.26% year-over-year from $4.1 million in Q4 2024, and down 60.96% quarter-over-quarter from $2.9 million in Q3 2025.
Jasper Therapeutics (JSPR) Non-Current Assets (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $1.1 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 72.26% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $12.0 million (down 38.97% YoY), while the FY2025 annual figure was $1.1 million, down 72.26% from the prior year.
- Non-Current Assets for Q4 2025 stood at $1.1 million, down from $2.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $100.2 million in Q1 2021, with the low at $1.1 million in Q4 2025.
- The 5-year median for Non-Current Assets is $5.6 million (2023), against an average of $14.6 million.
- Peak annual rise in Non-Current Assets reached 117.93% in 2021, while the deepest fall reached 95.21% in 2021.
- Jasper Therapeutics' Non-Current Assets stood at $5.8 million in 2021, then increased by 13.86% to $6.6 million in 2022, then retreated by 10.2% to $6.0 million in 2023, then slumped by 31.34% to $4.1 million in 2024, then slumped by 72.26% to $1.1 million in 2025.
- Business Quant data shows JSPR's Non-Current Assets at $1.1 million in Q4 2025, $2.9 million in Q3 2025, and $3.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Jasper Therapeutics | 20.06 Mn | 20.06 Mn | - | 231,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 4.42 Mn |
| Dec 31, 2024 | 4.09 Mn |
| Sep 30, 2024 | 4.61 Mn |
| Jun 30, 2024 | 5.25 Mn |
| Mar 31, 2024 | 5.66 Mn |
| Dec 31, 2023 | 5.95 Mn |
| Sep 30, 2023 | 5.19 Mn |
| Jun 30, 2023 | 5.60 Mn |
| Mar 31, 2023 | 6.25 Mn |
| Dec 31, 2022 | 6.63 Mn |
| Sep 30, 2022 | 6.70 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | 6.75 Mn |
| Dec 31, 2021 | 5.82 Mn |
| Sep 30, 2021 | 4.81 Mn |
| Jun 30, 2021 | 100.13 Mn |
| Mar 31, 2021 | 100.20 Mn |